{"gene":"MUC1","run_date":"2026-06-10T05:19:51","timeline":{"discoveries":[{"year":2007,"finding":"MUC1-C (C-terminal subunit) is N-glycosylated at Asn-36, and this N-glycosylation is required for upregulation of galectin-3 expression. N-glycosylated MUC1-C increases galectin-3 mRNA levels by suppressing miR-322, thereby stabilizing galectin-3 transcripts. In turn, galectin-3 binds to MUC1-C at the glycosylated Asn-36 site and forms a bridge between MUC1 and EGFR, making galectin-3 essential for EGF-mediated MUC1–EGFR interaction.","method":"In vitro glycosylation assays, miRNA suppression experiments, co-immunoprecipitation, mutagenesis of Asn-36","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, mutagenesis of glycosylation site, miRNA mechanistic follow-up, multiple orthogonal methods in single study","pmids":["17889671"],"is_preprint":false},{"year":2006,"finding":"The MUC1 C-terminal subunit (MUC1-C) directly binds the ERα DNA-binding domain, stabilizes ERα by blocking its ubiquitination and proteasomal degradation, enhances ERα occupancy on estrogen-responsive promoters, and increases recruitment of p160 coactivators SRC-1 and GRIP1, thereby stimulating ERα-mediated transcription. The interaction is stimulated by 17β-estradiol.","method":"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), ubiquitination assay, transcription reporter assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct binding demonstrated, ChIP showing promoter occupancy, ubiquitination assay, multiple orthogonal methods in single study","pmids":["16427018"],"is_preprint":false},{"year":2011,"finding":"MUC1-C associates with the gp130–JAK1–STAT3 complex; the MUC1-C cytoplasmic domain directly interacts with JAK1 and STAT3, and MUC1-C is required for JAK1-mediated STAT3 activation. In turn, activated STAT3 and MUC1-C co-occupy the MUC1 promoter, forming an autoinductive loop that drives MUC1 transcription.","method":"Co-immunoprecipitation of endogenous proteins, ChIP, siRNA knockdown, inhibitor (GO-201) treatment","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, ChIP, loss-of-function, multiple orthogonal methods in single study","pmids":["21325207"],"is_preprint":false},{"year":2015,"finding":"MUC1-C binds directly to TAK1 and mediates association of TAK1 with TRAF6, activating NF-κB-mediated TAK1 transcription; in a positive feedback loop, TAK1-induced NF-κB signaling is further promoted by MUC1-C, linking MUC1-C to inflammatory NF-κB signaling in colon cancer.","method":"Co-immunoprecipitation, gene knockdown, NF-κB reporter assay, in vivo MUC1+/−/IL-10−/− mouse model","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding by Co-IP, in vivo model, reporter assay, multiple orthogonal methods","pmids":["25659581"],"is_preprint":false},{"year":2008,"finding":"The Met receptor tyrosine kinase directly phosphorylates tyrosine at the YHPM motif in the MUC1 cytoplasmic tail (MUC1CT). HGF stimulation facilitates nuclear localization of MUC1CT. Met-phosphorylated MUC1CT enhances interaction with p53 and suppresses AP-1 activity at the MMP1 promoter, reducing MMP1 transcription and HGF-induced invasiveness.","method":"Co-immunoprecipitation, in vitro kinase assay, real-time confocal imaging for nuclear localization, ChIP/promoter reporter assay, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro kinase assay, live imaging, ChIP, multiple orthogonal methods in one study","pmids":["18625714"],"is_preprint":false},{"year":2006,"finding":"MUC1 is dually palmitoylated at a CQC motif at the boundary of the transmembrane and cytoplasmic domains. Palmitoylation is not required for MUC1 delivery to the cell surface or endocytosis but is required for recycling from Rab11-positive endosomes back to the plasma membrane.","method":"[3H]palmitate metabolic labeling, mutagenesis of CQC motif, membrane trafficking rate constant calculations, EGFP-Rab11 co-localization, co-immunoprecipitation with AP-1","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical labeling, mutagenesis, quantitative trafficking assays, subcellular localization with functional consequence","pmids":["16507569"],"is_preprint":false},{"year":2009,"finding":"MUC1 is a substrate for gamma-secretase: after TACE/ADAM17 ectodomain shedding, the resulting 15 kDa membrane-bound C-terminal fragment (CTF15) undergoes presenilin-dependent gamma-secretase cleavage. Mature nicastrin (the substrate receptor of gamma-secretase) co-immunoprecipitates with CTF15. Gamma-secretase inhibition causes CTF15 accumulation; subsequent degradation is non-proteasomal.","method":"Gamma-secretase inhibitors, TACE/ADAM17 inhibitors, nicastrin siRNA knockdown, co-immunoprecipitation of nicastrin with CTF15, Western blotting for cleavage products","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitors, siRNA, co-IP, multiple orthogonal methods establishing sequential proteolytic processing","pmids":["19711367"],"is_preprint":false},{"year":2013,"finding":"PPARγ acts as an E3 ubiquitin ligase that binds MUC1-C and induces its proteasome-dependent ubiquitination and degradation, identifying Lys134 of MUC1-C as critical for PPARγ-mediated degradation; this terminates MUC1-C-mediated cell proliferation independently of PPARγ transcriptional activity.","method":"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (Lys134), proteasome inhibitor treatment, cell proliferation assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ubiquitination assay, mutagenesis, Co-IP, multiple orthogonal methods identifying the modification site","pmids":["24292674"],"is_preprint":false},{"year":2016,"finding":"MUC1-C drives MYC expression in multiple myeloma by occupying the MYC promoter via a β-catenin/TCF4-mediated mechanism; MUC1-C increases β-catenin occupancy on the MYC promoter and forms a complex with β-catenin and TCF4.","method":"CRISPR/Cas9 MUC1-C silencing, ChIP, co-immunoprecipitation, qRT-PCR, GO-203 inhibitor treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR KO, ChIP, Co-IP; multiple orthogonal methods; single lab","pmids":["26907633"],"is_preprint":false},{"year":2016,"finding":"MUC1-C drives BMI1 transcription by a MYC-dependent mechanism and blocks miR-200c-mediated BMI1 downregulation. MUC1-C directly binds BMI1 and promotes BMI1 occupancy on the CDKN2A (p16INK4a) promoter, linking MUC1-C to PRC1-mediated epigenetic silencing of p16INK4a.","method":"Co-immunoprecipitation, ChIP, miRNA reporter assay, gene silencing, inhibitor (GO-203) treatment","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding Co-IP, ChIP, miRNA mechanistic assays, multiple orthogonal methods","pmids":["27893710"],"is_preprint":false},{"year":2016,"finding":"MUC1-C associates with ZEB1 on the CRB3 promoter to repress CRB3 transcription. Loss of CRB3 suppresses the Hippo pathway (reduced LATS1/2 phosphorylation), activating YAP. MUC1-C then interacts with YAP, promotes YAP/β-catenin complex formation, and induces WNT target MYC expression.","method":"ChIP, co-immunoprecipitation, siRNA knockdown, promoter reporter assay, phosphorylation analysis","journal":"Molecular cancer research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, Co-IP, multiple loss-of-function experiments, multiple orthogonal methods","pmids":["27658423"],"is_preprint":false},{"year":2007,"finding":"MUC1 cytoplasmic tail sequesters β-catenin away from E-cadherin, reduces β-catenin nuclear translocation, decreases LEF-1 activation, and suppresses cyclin D1 and c-Myc expression, resulting in inhibition of cell proliferation.","method":"Transfection of MUC1 cytoplasmic tail (CD8/MUC1 fusion), co-immunoprecipitation, luciferase reporter (LEF-1), Western blotting for cyclin D1/c-Myc, proliferation assay with Muc1+/+ vs. Muc1−/− primary cells","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, reporter assay, KO comparison, multiple orthogonal methods","pmids":["17524503"],"is_preprint":false},{"year":2004,"finding":"MUC1 (CD227) cytoplasmic domain is tyrosine-phosphorylated upon T cell receptor (TCR) ligation and associates with the Src-family kinase p56lck in Jurkat T cells and normal human T cells. MUC1 knockdown by siRNA reduces TCR-mediated Ca2+ influx, ERK1/2 phosphorylation, CD69 expression, proliferation, and IL-2 production.","method":"Co-immunoprecipitation of MUC1 with p56lck, low-density membrane fractionation, siRNA knockdown, flow cytometry, Ca2+ flux measurement","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, membrane fractionation, siRNA with defined signaling readouts, multiple orthogonal methods","pmids":["15513966"],"is_preprint":false},{"year":2001,"finding":"Muc1 mucins expressed on the cell surface serve as adhesion sites for Pseudomonas aeruginosa; deletion of the extracellular domain by mutation or proteolytic cleavage with neutrophil elastase abolishes bacterial adhesion to Muc1-expressing CHO cells.","method":"Stable transfection of hamster Muc1 cDNA into CHO cells, bacterial adhesion assay, neutrophil elastase cleavage, extracellular domain deletion mutant","journal":"American journal of physiology. Lung cellular and molecular physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional adhesion assay with deletion mutagenesis and enzymatic cleavage, clear mechanistic dissection","pmids":["11133508"],"is_preprint":false},{"year":2007,"finding":"Neutrophil elastase stimulates MUC1 transcription in lung epithelial cells via a PKCδ→Duox1→ROS→TACE→TNF-α→TNFR1→ERK1/2→Sp1 signaling pathway, distinct from the MUC5AC pathway which shares components only up to TACE.","method":"Pharmacological inhibitors, dominant-negative mutants, RNA interference, soluble receptor blocking, transcription reporter assay","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple inhibitors, dominant-negative mutants, RNAi, and reporter assays defining a complete pathway in one study","pmids":["17600314"],"is_preprint":false},{"year":2019,"finding":"TGF-β1 phosphorylates SMAD3, which increases phosphorylation of MUC1-CT at Thr41 and Tyr46, activating β-catenin to form phospho-SMAD3/MUC1-CT and MUC1-CT/β-catenin nuclear complexes that promote myofibroblast transition, cell senescence, and fibroblast proliferation. Galectin-3 directly activates MUC1-CT and serves as a bridge between the TGF-β receptor and MUC1-C, providing TGF-β1-independent activation. Inhibition of MUC1-CT nuclear translocation (GO-201 or siRNA) or Muc1 knockout reduces bleomycin-induced lung fibrosis.","method":"Phosphorylation analysis (Thr41/Tyr46), co-immunoprecipitation, nuclear fractionation, siRNA, GO-201 inhibitor, MUC1-knockout mice + bleomycin model, in vitro myofibroblast transition assays","journal":"Thorax","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro mechanistic dissection with phospho-specific analysis, Co-IP, in vivo KO model, multiple orthogonal methods across two laboratories' contexts","pmids":["31801904"],"is_preprint":false},{"year":2015,"finding":"In ischemia-reperfusion injury, Muc1 translocates from the apical surface to the cytoplasm and nucleus of renal tubular epithelia. Muc1 knockout mice show worse kidney damage, reduced HIF-1α levels, reduced induction of HIF-1 target glycolytic genes, and prolonged AMPK activation, indicating that Muc1 enhances the HIF-1α protective pathway during ischemic stress.","method":"Immunofluorescence localization (apical→cytoplasmic/nuclear shift), Muc1 knockout mice + IRI model, HIF-1α protein measurement, qPCR for HIF-1 target genes, AMPK activation assay","journal":"American journal of physiology. Renal physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct localization with functional consequence, KO mouse phenotype, multiple molecular readouts","pmids":["25925251"],"is_preprint":false},{"year":2020,"finding":"MUC1-C upregulates CDA (cytidine deaminase) expression by occupying the CDA promoter upon ER stress induction, increasing CDA activity and driving deoxycytidine-to-deoxyuridine metabolic reprogramming. The resulting deoxyuridine mitigates ER stress-induced cytotoxicity and ROS, providing cancer cell survival advantage.","method":"ChIP showing MUC1-C occupancy on CDA promoter, CDA activity assay, transcriptomic analysis, metabolomic analysis, MUC1 knockdown, CDA/pathway inhibitors","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — ChIP, enzymatic activity assay, metabolomics, loss-of-function; multiple orthogonal methods","pmids":["32103170"],"is_preprint":false},{"year":2016,"finding":"MUC1 stimulates EGFR gene expression in endometrial cancer: MUC1 directly binds to two regions of the EGFR promoter (−627/−511 and −172/−64), and MUC1 knockout (CRISPR/Cas9) or siRNA knockdown reduces EGFR mRNA, protein, and downstream signaling.","method":"siRNA knockdown, CRISPR/Cas9 knockout, ChIP showing MUC1 binding to EGFR promoter, Western blotting, qPCR, proliferation assay","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP, CRISPR KO, siRNA, multiple functional readouts; single lab, orthogonal methods","pmids":["27092881"],"is_preprint":false},{"year":2020,"finding":"MUC1-C suppresses androgen receptor (AR) axis signaling and induces BRN2 via a MYC→BRN2 pathway; it also induces MYCN, EZH2, and neuroendocrine markers (ASCL1, AURKA, SYP), suppresses p53, and induces Yamanaka pluripotency factors (OCT4, SOX2, KLF4, MYC), driving cancer stem cell self-renewal and lineage plasticity toward neuroendocrine prostate cancer.","method":"siRNA knockdown, CRISPR editing, inhibitor treatment, ChIP for promoter occupancy, gene expression analysis, self-renewal (sphere formation) and tumorigenicity assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR, ChIP, multiple signaling readouts; single lab with multiple orthogonal methods","pmids":["31953400"],"is_preprint":false},{"year":2009,"finding":"MUC1-C binds directly to β-catenin and EGFR through tandem sequences in its cytoplasmic domain; a MUC1 inhibitory peptide (PMIP) blocks both MUC1/β-catenin and MUC1/EGFR interactions in a dominant-negative fashion, induces ligand-dependent EGFR degradation, and reduces breast cancer cell proliferation, migration, invasion, and tumor growth in vivo.","method":"Peptide competition assay, co-immunoprecipitation, receptor degradation assay, in vitro proliferation/migration/invasion assays, SCID mouse xenograft model, MMTV-pyVmT transgenic mouse model","journal":"Clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP with peptide competition, in vivo mouse models, multiple cell-based phenotypic assays","pmids":["19118037"],"is_preprint":false},{"year":1999,"finding":"Muc1 null mice develop bacterial conjunctivitis (coagulase-negative Staphylococcus, Streptococcus type alpha, Corynebacterium group G2) at significantly higher rates than wild-type mice, establishing that Muc1 plays a critical protective role at the ocular epithelial surface against bacterial infection.","method":"Muc1 knockout mouse model, bacterial speciation of infected tissue, immunofluorescence for Muc1 protein in conjunctiva/Harderian gland, Northern blot/RT-PCR for transcript","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO mouse model with defined infectious phenotype, molecular confirmation of Muc1 in affected tissue","pmids":["10359313"],"is_preprint":false},{"year":2016,"finding":"MUC1/Muc1 is predominantly expressed in classically activated (M1) macrophages; MUC1/Muc1-deficiency increases macrophage adhesion and phagocytosis of P. aeruginosa and E. coli, and augments ROS production and TNF-α release, demonstrating that MUC1 counter-regulates macrophage phagocytic activity in an anti-inflammatory manner. M1 polarization and Pa stimulation increase MUC1 ectodomain shedding via TACE.","method":"Muc1 knockout macrophages (M0/M1/M2 polarization), phagocytosis assays, ROS measurement, ELISA for TNF-α, TACE inhibitor, flow cytometry","journal":"American journal of respiratory cell and molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — KO cells with defined functional readouts, multiple cell types, pharmacological confirmation of shedding mechanism","pmids":["26393683"],"is_preprint":false},{"year":1996,"finding":"A secreted MUC1 isoform (MUC1/SEC), produced by alternative splicing incorporating intron 2 sequence and lacking a transmembrane domain, is expressed at the protein level by breast cancer cells and is detectable in sera of breast cancer patients.","method":"Generation of isoform-specific monoclonal antibodies against the unique sec peptide, Western blotting of secreted proteins, immunoreactivity with recombinant MUC1/SEC, inhibition by sec peptide","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific antibodies, recombinant protein validation, peptide competition; single lab","pmids":["8912645"],"is_preprint":false},{"year":2002,"finding":"MUC1 cytoplasmic domain is tyrosine-phosphorylated in activated human T cells and dendritic cells (DC), and associates with other phosphoproteins, indicating a role in signal transduction in these hematopoietic cells.","method":"Flow cytometry for CD227 expression, phosphotyrosine Western blotting of CD227 immunoprecipitates from activated T cells and DC, in vitro DC culture activation","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP/phosphoblot, confirmed in two cell types (T cells and DC), single lab","pmids":["12377938"],"is_preprint":false},{"year":2017,"finding":"MUC1 induces acquired chemoresistance by upregulating ABCB1 (P-glycoprotein) through EGFR activation and nuclear translocation; targeted suppression of EGFR or ABCB1 reverses MUC1-mediated drug resistance in vitro and in xenograft models.","method":"Gain- and loss-of-function MUC1 models, shRNA and inhibitors targeting EGFR and ABCB1, xenograft mouse model, Western blotting for EGFR nuclear translocation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss/gain-of-function, in vivo model, pharmacological rescue; single lab, pathway inferred from inhibitor experiments","pmids":["28796259"],"is_preprint":false},{"year":2017,"finding":"MUC1 expression enhances glycolysis, pentose phosphate pathway flux, and nucleotide biosynthesis in pancreatic cancer cells, conferring radiation resistance by maintaining high nucleotide pools and reducing DNA damage; glycolysis inhibition with 3-bromopyruvate abrogates MUC1-mediated radiation resistance both in vitro and in vivo.","method":"MUC1 knockdown and overexpression models, metabolomic analysis, clonogenicity and cytotoxicity assays, DNA damage (γH2AX) measurement, 3-bromopyruvate rescue in vitro and in vivo xenograft","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolomics, functional rescue with glycolysis inhibitor, in vivo model; single lab","pmids":["28720669"],"is_preprint":false},{"year":1998,"finding":"Muc1 expression in rabbit uterine epithelium is upregulated ~10-fold by progesterone and dramatically reduced locally at implantation sites; blastocyst-derived signals (demonstrated by coculture of uterine epithelial cells with trophoblastic vesicles) locally remove Muc1 from the apical epithelial surface, facilitating embryo attachment.","method":"Northern blot for Muc1 mRNA at defined pregnancy stages, immunofluorescence localization, short-term coculture of uterine epithelial cells with trophoblastic vesicles","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — Northern blot quantitation, immunofluorescence, and ex vivo coculture; single lab with multiple complementary approaches","pmids":["9421424"],"is_preprint":false},{"year":2022,"finding":"YBX1 transcription factor directly binds the MUC1 promoter at position −1480/−1476 and activates MUC1 transcription, contributing to lung adenocarcinoma stemness and metastasis downstream of YBX1.","method":"ChIP assay, dual-luciferase reporter assay, YBX1 silencing/overexpression with MUC1 rescue, xenograft and metastasis mouse models","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay define direct transcriptional regulation; single lab","pmids":["34976785"],"is_preprint":false},{"year":2022,"finding":"MUC1-C enhances stability of EGFRvIII in glioblastoma by preventing its lysosomal degradation; MUC1-C knockdown increases EGFRvIII-lysosome colocalization. MUC1-C upregulation in EGFRvIII-positive cells occurs via NF-κB, forming a positive feedback loop between EGFRvIII and MUC1.","method":"CRISPR-Cas9 library screening, siRNA knockdown, immunofluorescence colocalization with lysosome markers, NF-κB pathway inhibitor, Western blotting","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen, siRNA, colocalization; single lab, mechanism partially inferred","pmids":["36516884"],"is_preprint":false},{"year":2012,"finding":"MUC1 and c-Met interact physically in hepatocellular carcinoma (HCC) cells; HGF-induced c-Met phosphorylation decreases this interaction and downregulates MUC1 expression. Conversely, MUC1 siRNA silencing increases HGF-induced c-Met activation and cell motility/invasion via the β-catenin/c-Myc pathway.","method":"Co-immunoprecipitation of MUC1 and c-Met, siRNA silencing, c-Met inhibitor, migration/invasion assays, β-catenin/c-Myc Western blotting","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP, siRNA with functional readouts, pharmacological inhibition; single lab","pmids":["22962849"],"is_preprint":false}],"current_model":"MUC1 is a heterodimeric transmembrane mucin whose N-terminal subunit (MUC1-N) forms a protective apical mucous barrier, while the C-terminal subunit (MUC1-C) acts as a signaling hub: it is proteolytically shed by TACE/ADAM17 and further cleaved by presenilin-dependent gamma-secretase; the cytoplasmic tail undergoes tyrosine phosphorylation by kinases including Met and Lck, serine/threonine phosphorylation by TGF-β/SMAD3, and S-palmitoylation at a CQC motif that controls endosomal recycling; phosphorylated MUC1-C directly interacts with ERα, JAK1, STAT3, β-catenin, TCF4, BMI1, TAK1/TRAF6, p56lck, galectin-3/EGFR, and p53 to modulate transcription (ERα target genes, MYC, STAT3, NF-κB/TAK1, CRB3, CDA, EGFR), epigenetic reprogramming (PRC1/BMI1-H2A ubiquitylation, p16INK4a silencing), metabolic reprogramming (glycolysis, nucleotide biosynthesis, pyrimidine metabolism via CDA), and cellular processes including cell polarity loss, inflammation, stem cell self-renewal, and lineage plasticity; in normal epithelia MUC1 serves as a bacterial adhesion/binding site and counter-regulates excessive TLR-mediated inflammation, protects renal tubules during ischemia via HIF-1α enhancement, and its surface expression is dynamically controlled by progesterone and blastocyst-derived signals in the uterus."},"narrative":{"mechanistic_narrative":"MUC1 is a transmembrane mucin processed into two subunits whose membrane-tethered C-terminal subunit (MUC1-C) functions as a signal-transducing oncoprotein, while the cell-surface ectodomain provides a protective epithelial barrier [PMID:11133508, PMID:19118037]. At the surface, MUC1 serves as an adhesion site for bacteria such as Pseudomonas aeruginosa and counter-regulates inflammatory responses, with knockout animals showing increased ocular and conjunctival infection and macrophage hyperactivation [PMID:11133508, PMID:10359313, PMID:26393683]. MUC1-C is subject to sequential proteolytic processing: TACE/ADAM17 sheds the ectodomain to generate a membrane-bound C-terminal fragment that is then cleaved by presenilin-dependent gamma-secretase [PMID:19711367, PMID:26393683]. Its cytoplasmic tail is a phosphorylation hub, tyrosine-phosphorylated by the Met receptor and by the Src-family kinase p56lck following T-cell receptor ligation, and serine/threonine-phosphorylated downstream of TGF-β1/SMAD3, with N-glycosylation at Asn-36 and palmitoylation at a CQC motif governing galectin-3-bridged EGFR association and Rab11-dependent endosomal recycling, respectively [PMID:17889671, PMID:18625714, PMID:16507569, PMID:15513966, PMID:31801904]. Once activated, MUC1-C directly binds an array of transcriptional and signaling partners—ERα, JAK1/STAT3, TAK1/TRAF6, β-catenin/TCF4, BMI1, YAP/ZEB1, and p53—to drive target-gene programs including ERα-responsive genes, MYC, EGFR, CDA, and NF-κB-dependent transcription, frequently through autoinductive feedback loops [PMID:16427018, PMID:21325207, PMID:25659581, PMID:26907633, PMID:27893710, PMID:27658423, PMID:27092881]. Through these circuits MUC1-C promotes epigenetic silencing of CDKN2A/p16INK4a via PRC1/BMI1, metabolic reprogramming toward glycolysis and nucleotide biosynthesis, and cancer stem-cell self-renewal and neuroendocrine lineage plasticity [PMID:27893710, PMID:32103170, PMID:19118037, PMID:28720669]. In normal physiology MUC1 enhances HIF-1α-mediated protection of renal tubules during ischemia, while its expression is hormonally and developmentally controlled at the uterine surface during implantation [PMID:25925251, PMID:9421424]. MUC1-C abundance is itself terminated by PPARγ-mediated ubiquitination at Lys134 [PMID:24292674].","teleology":[{"year":1996,"claim":"Established that MUC1 is not exclusively membrane-bound, defining a secreted splice isoform detectable in cancer patient sera and broadening the protein's potential extracellular roles.","evidence":"Isoform-specific monoclonal antibodies and Western blotting of breast cancer secretions and patient sera","pmids":["8912645"],"confidence":"Medium","gaps":["Functional role of the secreted isoform not defined","Relationship to the transmembrane signaling functions unclear"]},{"year":1998,"claim":"Resolved how MUC1 surface levels are regulated in reproduction, showing hormonal induction and local embryo-driven removal to permit implantation.","evidence":"Northern blot, immunofluorescence, and uterine epithelial/trophoblastic vesicle coculture in rabbit","pmids":["9421424"],"confidence":"Medium","gaps":["Molecular nature of the blastocyst-derived signal not identified","Mechanism of local MUC1 removal undefined"]},{"year":1999,"claim":"Defined MUC1's protective barrier function in vivo, demonstrating that its loss predisposes epithelial surfaces to bacterial infection.","evidence":"Muc1 knockout mice with bacterial speciation of conjunctival infection","pmids":["10359313"],"confidence":"High","gaps":["Molecular basis of anti-bacterial protection not dissected here"]},{"year":2001,"claim":"Identified the molecular basis of MUC1's barrier role by showing the ectodomain acts as a bacterial adhesion site.","evidence":"Muc1 transfection of CHO cells, bacterial adhesion assays, elastase cleavage and deletion mutants","pmids":["11133508"],"confidence":"High","gaps":["Receptor/ligand pairing with bacterial adhesins not defined","Whether adhesion is protective or facilitates colonization not resolved"]},{"year":2004,"claim":"Showed the MUC1 cytoplasmic tail participates in immune signal transduction, linking it to TCR-proximal kinase activity.","evidence":"Co-IP with p56lck, membrane fractionation, siRNA with Ca2+ flux/ERK/CD69/IL-2 readouts in T cells","pmids":["15513966"],"confidence":"High","gaps":["Direct kinase-substrate phosphorylation site on MUC1 not mapped","Whether p56lck phosphorylates MUC1 directly not shown"]},{"year":2006,"claim":"Established MUC1-C as a direct transcriptional cofactor by showing it stabilizes ERα and enhances estrogen-responsive transcription.","evidence":"Co-IP, ChIP, ubiquitination and reporter assays with 17β-estradiol stimulation","pmids":["16427018"],"confidence":"High","gaps":["Whether nuclear MUC1-C requires prior cleavage not addressed","Generality across non-breast contexts unknown"]},{"year":2006,"claim":"Defined a post-translational control of MUC1 trafficking, showing palmitoylation at the CQC motif governs endosomal recycling.","evidence":"[3H]palmitate labeling, CQC mutagenesis, trafficking rate constants, Rab11 colocalization, AP-1 Co-IP","pmids":["16507569"],"confidence":"High","gaps":["Palmitoyltransferase responsible not identified","Link between recycling and signaling output not established"]},{"year":2007,"claim":"Connected MUC1-C glycosylation to receptor signaling, showing Asn-36 N-glycosylation enables galectin-3-bridged MUC1–EGFR association.","evidence":"Glycosylation assays, Asn-36 mutagenesis, miR-322 suppression, reciprocal Co-IP","pmids":["17889671"],"confidence":"High","gaps":["Structural basis of the galectin-3 bridge not resolved"]},{"year":2007,"claim":"Revealed a tumor-suppressive facet of the cytoplasmic tail by showing it sequesters β-catenin to restrain proliferative transcription.","evidence":"CD8/MUC1 fusion transfection, Co-IP, LEF-1 reporter, Muc1+/+ vs -/- proliferation","pmids":["17524503"],"confidence":"High","gaps":["Reconciliation with later β-catenin/TCF4-driven MYC activation context-dependent and unresolved"]},{"year":2007,"claim":"Mapped a complete signaling cascade by which neutrophil elastase induces MUC1 transcription, distinguishing it from MUC5AC regulation.","evidence":"Inhibitors, dominant-negatives, RNAi, and reporter assays in lung epithelial cells","pmids":["17600314"],"confidence":"High","gaps":["In vivo relevance of the PKCδ→Duox1→TACE→Sp1 axis not tested"]},{"year":2008,"claim":"Identified Met as a direct MUC1 cytoplasmic-tail kinase and linked HGF signaling to nuclear MUC1 and p53-dependent transcriptional output.","evidence":"In vitro kinase assay, live-cell nuclear imaging, ChIP/reporter at MMP1 promoter","pmids":["18625714"],"confidence":"High","gaps":["How phosphorylation drives nuclear import mechanistically not defined"]},{"year":2009,"claim":"Completed the proteolytic processing model by demonstrating gamma-secretase cleaves the membrane-bound MUC1 C-terminal fragment after ectodomain shedding.","evidence":"Gamma-secretase and TACE inhibitors, nicastrin siRNA and Co-IP, cleavage-product Westerns","pmids":["19711367"],"confidence":"High","gaps":["Fate and signaling role of the released intracellular fragment not defined"]},{"year":2009,"claim":"Pinpointed tandem cytoplasmic sequences mediating direct β-catenin and EGFR binding and validated them as druggable with a dominant-negative peptide.","evidence":"Peptide competition, Co-IP, EGFR degradation assay, xenograft and MMTV-pyVmT models","pmids":["19118037"],"confidence":"High","gaps":["Structural detail of the binding interfaces not resolved"]},{"year":2011,"claim":"Showed MUC1-C is required for JAK1-driven STAT3 activation and forms an autoinductive transcriptional loop at its own promoter.","evidence":"Reciprocal Co-IP, ChIP, siRNA, GO-201 inhibitor","pmids":["21325207"],"confidence":"High","gaps":["Whether MUC1-C directly enhances JAK1 catalytic activity not shown"]},{"year":2012,"claim":"Demonstrated context-dependence of the MUC1–c-Met axis, with MUC1 restraining HGF-induced c-Met activation and invasion in HCC.","evidence":"Co-IP, siRNA, c-Met inhibitor, migration/invasion assays in HCC cells","pmids":["22962849"],"confidence":"Medium","gaps":["Single Co-IP without reciprocal validation in this system","Reconciliation with Met-driven pro-tumor MUC1 signaling elsewhere unresolved"]},{"year":2013,"claim":"Identified a mechanism terminating MUC1-C signaling, revealing PPARγ as an E3 ligase that ubiquitinates MUC1-C at Lys134 for degradation.","evidence":"Co-IP, ubiquitination assay, Lys134 mutagenesis, proteasome inhibitor, proliferation assay","pmids":["24292674"],"confidence":"High","gaps":["Physiological signals controlling PPARγ ligase activity toward MUC1-C unknown"]},{"year":2015,"claim":"Linked MUC1-C to inflammatory NF-κB signaling via direct TAK1/TRAF6 binding in a positive feedback loop relevant to colon cancer.","evidence":"Co-IP, knockdown, NF-κB reporter, MUC1+/-/IL-10-/- mouse model","pmids":["25659581"],"confidence":"High","gaps":["Whether MUC1-C enhances TAK1 kinase activity directly not shown"]},{"year":2015,"claim":"Defined a cytoprotective role in renal ischemia, showing MUC1 traffics to the nucleus and enhances HIF-1α stabilization and glycolytic gene induction.","evidence":"Immunofluorescence localization, Muc1 KO + IRI model, HIF-1α and AMPK measurements","pmids":["25925251"],"confidence":"High","gaps":["Direct MUC1–HIF-1α interaction not demonstrated","Mechanism of HIF-1α stabilization unresolved"]},{"year":2016,"claim":"Established a MUC1-C/β-catenin/TCF4 transcriptional mechanism driving MYC in multiple myeloma.","evidence":"CRISPR silencing, ChIP, Co-IP, qRT-PCR, GO-203 inhibitor","pmids":["26907633"],"confidence":"High","gaps":["Determinants of β-catenin promoter recruitment by MUC1-C not defined"]},{"year":2016,"claim":"Linked MUC1-C to PRC1-mediated epigenetic silencing of p16INK4a through MYC-dependent BMI1 induction and direct BMI1 binding.","evidence":"Co-IP, ChIP, miR-200c reporter, gene silencing, GO-203","pmids":["27893710"],"confidence":"High","gaps":["Direct effect on H2A ubiquitylation not measured here"]},{"year":2016,"claim":"Connected MUC1-C to Hippo/YAP and WNT crosstalk by repressing CRB3 with ZEB1 and forming YAP/β-catenin complexes.","evidence":"ChIP, Co-IP, siRNA, promoter reporter, LATS1/2 phosphorylation analysis","pmids":["27658423"],"confidence":"High","gaps":["Order of events between CRB3 repression and polarity loss not fully resolved"]},{"year":2016,"claim":"Showed MUC1 acts as a direct transcriptional activator of EGFR by binding its promoter in endometrial cancer.","evidence":"siRNA, CRISPR KO, ChIP at two EGFR promoter regions, qPCR/Western, proliferation","pmids":["27092881"],"confidence":"High","gaps":["Cofactors required for MUC1 promoter occupancy not identified"]},{"year":2016,"claim":"Defined MUC1 as an anti-inflammatory counter-regulator of macrophage phagocytosis and cytokine output, predominantly in M1 macrophages.","evidence":"Muc1 KO macrophages, phagocytosis/ROS/TNF-α assays, TACE inhibitor","pmids":["26393683"],"confidence":"High","gaps":["Downstream signaling restraining phagocytosis not mapped"]},{"year":2017,"claim":"Linked MUC1 to acquired chemoresistance via EGFR-driven ABCB1 upregulation.","evidence":"Gain/loss-of-function, EGFR/ABCB1 shRNA and inhibitors, xenografts","pmids":["28796259"],"confidence":"Medium","gaps":["Pathway inferred from inhibitor experiments rather than direct binding","Direct MUC1 occupancy at ABCB1 not shown"]},{"year":2017,"claim":"Established MUC1-driven metabolic reprogramming as a basis for radiation resistance through elevated glycolysis and nucleotide pools.","evidence":"Knockdown/overexpression, metabolomics, γH2AX, 3-bromopyruvate rescue in vitro and in vivo","pmids":["28720669"],"confidence":"Medium","gaps":["Transcriptional/enzymatic targets mediating glycolytic shift not all defined"]},{"year":2019,"claim":"Defined a TGF-β1/SMAD3 phosphorylation mechanism on MUC1-CT (Thr41/Tyr46) driving fibrosis, with galectin-3 providing a TGF-β-independent bridge.","evidence":"Phospho-specific analysis, Co-IP, nuclear fractionation, siRNA/GO-201, Muc1 KO + bleomycin model","pmids":["31801904"],"confidence":"High","gaps":["Kinase directly phosphorylating Tyr46 downstream of SMAD3 not identified"]},{"year":2020,"claim":"Connected MUC1-C to pyrimidine metabolic reprogramming under ER stress by transcriptionally activating CDA for survival.","evidence":"ChIP at CDA promoter, CDA activity assay, transcriptomics/metabolomics, knockdown, inhibitors","pmids":["32103170"],"confidence":"High","gaps":["Cofactors recruiting MUC1-C to the CDA promoter not defined"]},{"year":2020,"claim":"Established MUC1-C as a driver of lineage plasticity and stemness, suppressing AR and p53 while inducing pluripotency and neuroendocrine programs.","evidence":"siRNA, CRISPR, ChIP, sphere formation and tumorigenicity assays in prostate cancer","pmids":["31953400"],"confidence":"High","gaps":["Hierarchy among the many induced factors not fully ordered"]},{"year":2022,"claim":"Identified YBX1 as a direct upstream transcriptional activator of MUC1 contributing to lung adenocarcinoma stemness and metastasis.","evidence":"ChIP, dual-luciferase reporter, YBX1 silencing/overexpression with MUC1 rescue, mouse models","pmids":["34976785"],"confidence":"Medium","gaps":["Single-lab finding; broader generality of YBX1 control of MUC1 untested"]},{"year":2022,"claim":"Revealed a post-translational MUC1-C function stabilizing EGFRvIII against lysosomal degradation within an NF-κB feedback loop in glioblastoma.","evidence":"CRISPR screen, siRNA, lysosome colocalization, NF-κB inhibitor, Western blotting","pmids":["36516884"],"confidence":"Medium","gaps":["Mechanism by which MUC1-C diverts EGFRvIII from lysosomes not defined","Mechanism partially inferred"]},{"year":null,"claim":"How MUC1-C reconciles its context-dependent tumor-suppressive (β-catenin sequestration, c-Met restraint) versus oncogenic (β-catenin/TCF4-MYC, EGFR amplification) roles, and the structural basis of its many direct interactions, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of MUC1-C interaction interfaces","Determinants switching MUC1-C between suppressive and oncogenic outputs unknown","Rules governing nuclear translocation versus membrane signaling undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,8,9,17,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,3,4,12]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[13]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,3,8]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,13,16]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,15,16]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[16]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,4,12,20]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,2,8,9,17,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[12,21,22]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[6,7]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,26]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[9]}],"complexes":[],"partners":["EGFR","CTNNB1","STAT3","JAK1","ESR1","TCF4","BMI1","TAK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P15941","full_name":"Mucin-1","aliases":["Breast carcinoma-associated antigen DF3","Cancer antigen 15-3","CA 15-3","Carcinoma-associated mucin","Episialin","H23AG","Krebs von den Lungen-6","KL-6","PEMT","Peanut-reactive urinary mucin","PUM","Polymorphic epithelial mucin","PEM","Tumor-associated epithelial membrane antigen","EMA","Tumor-associated mucin"],"length_aa":1255,"mass_kda":122.1,"function":"The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity","subcellular_location":"Cell membrane; Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P15941/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MUC1","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MUC1","total_profiled":1310},"omim":[{"mim_id":"618061","title":"POLYCYSTIC KIDNEY DISEASE 6 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE; PKD6","url":"https://www.omim.org/entry/618061"},{"mim_id":"616991","title":"MUCIN 21, CELL SURFACE-ASSOCIATED; MUC21","url":"https://www.omim.org/entry/616991"},{"mim_id":"615315","title":"BETA-1,3-N-ACETYLGLUCOSAMINYLTRANSFERASE 6; B3GNT6","url":"https://www.omim.org/entry/615315"},{"mim_id":"614633","title":"VPS54 SUBUNIT OF GARP COMPLEX; VPS54","url":"https://www.omim.org/entry/614633"},{"mim_id":"611341","title":"DNAJ/HSP40 HOMOLOG, SUBFAMILY B, MEMBER 11; DNAJB11","url":"https://www.omim.org/entry/611341"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"kidney","ntpm":416.9},{"tissue":"stomach 1","ntpm":998.2}],"url":"https://www.proteinatlas.org/search/MUC1"},"hgnc":{"alias_symbol":["CD227","PEM","ADMCKD","ADMCKD1","MCKD","MCD","KL-6","EMA","Ca15-3"],"prev_symbol":["PUM","MCKD1"]},"alphafold":{"accession":"P15941","domains":[{"cath_id":"3.30.70.960","chopping":"1041-1144","consensus_level":"high","plddt":84.3612,"start":1041,"end":1144}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P15941","model_url":"https://alphafold.ebi.ac.uk/files/AF-P15941-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P15941-F1-predicted_aligned_error_v6.png","plddt_mean":47.41},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MUC1","jax_strain_url":"https://www.jax.org/strain/search?query=MUC1"},"sequence":{"accession":"P15941","fasta_url":"https://rest.uniprot.org/uniprotkb/P15941.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P15941/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P15941"}},"corpus_meta":[{"pmid":"11547902","id":"PMC_11547902","title":"MUC1, the renaissance molecule.","date":"2001","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/11547902","citation_count":475,"is_preprint":false},{"pmid":"10571020","id":"PMC_10571020","title":"MUC1 and cancer.","date":"1999","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10571020","citation_count":386,"is_preprint":false},{"pmid":"14711375","id":"PMC_14711375","title":"MUC1: a multifunctional cell surface component of reproductive tissue epithelia.","date":"2004","source":"Reproductive biology and endocrinology : RB&E","url":"https://pubmed.ncbi.nlm.nih.gov/14711375","citation_count":224,"is_preprint":false},{"pmid":"34207342","id":"PMC_34207342","title":"MUC1: Structure, Function, and Clinic Application in Epithelial Cancers.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34207342","citation_count":209,"is_preprint":false},{"pmid":"9443411","id":"PMC_9443411","title":"Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9443411","citation_count":178,"is_preprint":false},{"pmid":"14570709","id":"PMC_14570709","title":"Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14570709","citation_count":172,"is_preprint":false},{"pmid":"17889671","id":"PMC_17889671","title":"The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17889671","citation_count":160,"is_preprint":false},{"pmid":"16427018","id":"PMC_16427018","title":"MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16427018","citation_count":158,"is_preprint":false},{"pmid":"23303343","id":"PMC_23303343","title":"MUC1 and metastatic cancer: expression, function and therapeutic targeting.","date":"2013","source":"Cell adhesion & migration","url":"https://pubmed.ncbi.nlm.nih.gov/23303343","citation_count":153,"is_preprint":false},{"pmid":"18027437","id":"PMC_18027437","title":"MUC1: a target molecule for cancer therapy.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18027437","citation_count":134,"is_preprint":false},{"pmid":"31953400","id":"PMC_31953400","title":"MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31953400","citation_count":127,"is_preprint":false},{"pmid":"12463741","id":"PMC_12463741","title":"MUC1 and the immunobiology of cancer.","date":"2002","source":"Journal of mammary gland biology and neoplasia","url":"https://pubmed.ncbi.nlm.nih.gov/12463741","citation_count":126,"is_preprint":false},{"pmid":"9421424","id":"PMC_9421424","title":"Progesterone and implanting blastocysts regulate Muc1 expression in rabbit uterine epithelium.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9421424","citation_count":126,"is_preprint":false},{"pmid":"8813954","id":"PMC_8813954","title":"Significance of MUC1 and MUC2 mucin expression in colorectal cancer.","date":"1996","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8813954","citation_count":111,"is_preprint":false},{"pmid":"26294353","id":"PMC_26294353","title":"MUC1 (CD227): a multi-tasked molecule.","date":"2015","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/26294353","citation_count":109,"is_preprint":false},{"pmid":"11133508","id":"PMC_11133508","title":"Muc1 mucins on the cell surface are adhesion sites for Pseudomonas aeruginosa.","date":"2001","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11133508","citation_count":108,"is_preprint":false},{"pmid":"15113850","id":"PMC_15113850","title":"MUC1 and MUC2 in pancreatic neoplasia.","date":"2004","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15113850","citation_count":106,"is_preprint":false},{"pmid":"9422987","id":"PMC_9422987","title":"Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours.","date":"1997","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9422987","citation_count":103,"is_preprint":false},{"pmid":"16883323","id":"PMC_16883323","title":"Alterations of uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD syndrome.","date":"2006","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/16883323","citation_count":98,"is_preprint":false},{"pmid":"21325207","id":"PMC_21325207","title":"MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21325207","citation_count":92,"is_preprint":false},{"pmid":"25659581","id":"PMC_25659581","title":"MUC1-C activates the TAK1 inflammatory pathway in colon cancer.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25659581","citation_count":90,"is_preprint":false},{"pmid":"10630311","id":"PMC_10630311","title":"MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines.","date":"2000","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/10630311","citation_count":90,"is_preprint":false},{"pmid":"7515892","id":"PMC_7515892","title":"Developmental expression of mucin genes MUC1 and MUC2.","date":"1994","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/7515892","citation_count":89,"is_preprint":false},{"pmid":"11192832","id":"PMC_11192832","title":"Human MUC1 mucin: a multifaceted glycoprotein.","date":"2000","source":"The International journal of biological markers","url":"https://pubmed.ncbi.nlm.nih.gov/11192832","citation_count":85,"is_preprint":false},{"pmid":"16302265","id":"PMC_16302265","title":"Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas.","date":"2006","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/16302265","citation_count":85,"is_preprint":false},{"pmid":"24418575","id":"PMC_24418575","title":"MUC1: a novel metabolic master regulator.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24418575","citation_count":83,"is_preprint":false},{"pmid":"22998452","id":"PMC_22998452","title":"MUC1 immunotherapy is here to stay.","date":"2012","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22998452","citation_count":83,"is_preprint":false},{"pmid":"28720669","id":"PMC_28720669","title":"MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28720669","citation_count":83,"is_preprint":false},{"pmid":"28796259","id":"PMC_28796259","title":"MUC1 induces acquired chemoresistance by upregulating ABCB1 in EGFR-dependent manner.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28796259","citation_count":82,"is_preprint":false},{"pmid":"10359313","id":"PMC_10359313","title":"Bacterial conjunctivitis in Muc1 null mice.","date":"1999","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10359313","citation_count":82,"is_preprint":false},{"pmid":"9872358","id":"PMC_9872358","title":"MUC1 and endometrial receptivity.","date":"1998","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/9872358","citation_count":79,"is_preprint":false},{"pmid":"18625714","id":"PMC_18625714","title":"Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18625714","citation_count":79,"is_preprint":false},{"pmid":"9441682","id":"PMC_9441682","title":"Posterior end mark 2 (pem-2), pem-4, pem-5, and pem-6: maternal genes with localized mRNA in the ascidian embryo.","date":"1997","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9441682","citation_count":72,"is_preprint":false},{"pmid":"7720039","id":"PMC_7720039","title":"Is episialin/MUC1 involved in breast cancer progression?","date":"1995","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/7720039","citation_count":72,"is_preprint":false},{"pmid":"29147108","id":"PMC_29147108","title":"MUC1 Aptamer Targeted SERS Nanoprobes.","date":"2017","source":"Advanced functional materials","url":"https://pubmed.ncbi.nlm.nih.gov/29147108","citation_count":69,"is_preprint":false},{"pmid":"26907633","id":"PMC_26907633","title":"MUC1-C drives MYC in multiple myeloma.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26907633","citation_count":68,"is_preprint":false},{"pmid":"12377938","id":"PMC_12377938","title":"MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells.","date":"2002","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12377938","citation_count":67,"is_preprint":false},{"pmid":"9769172","id":"PMC_9769172","title":"Normal reproductive and macrophage function in Pem homeobox gene-deficient mice.","date":"1998","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/9769172","citation_count":67,"is_preprint":false},{"pmid":"22962849","id":"PMC_22962849","title":"Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.","date":"2012","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22962849","citation_count":66,"is_preprint":false},{"pmid":"18617677","id":"PMC_18617677","title":"MUC1 mucin: a peacemaker in the lung.","date":"2008","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18617677","citation_count":62,"is_preprint":false},{"pmid":"38540735","id":"PMC_38540735","title":"The Role of MUC1 in Renal Cell Carcinoma.","date":"2024","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38540735","citation_count":61,"is_preprint":false},{"pmid":"14531790","id":"PMC_14531790","title":"Mutations of the Uromodulin gene in MCKD type 2 patients cluster in exon 4, which encodes three EGF-like domains.","date":"2003","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/14531790","citation_count":61,"is_preprint":false},{"pmid":"19118037","id":"PMC_19118037","title":"Intracellular MUC1 peptides inhibit cancer progression.","date":"2009","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/19118037","citation_count":61,"is_preprint":false},{"pmid":"20826587","id":"PMC_20826587","title":"MUC1 as a discriminator between endometrium from fertile and infertile patients with PCOS and endometriosis.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20826587","citation_count":61,"is_preprint":false},{"pmid":"27472370","id":"PMC_27472370","title":"Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines.","date":"2016","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/27472370","citation_count":59,"is_preprint":false},{"pmid":"29186029","id":"PMC_29186029","title":"MUC1: The First Respiratory Mucin with an Anti-Inflammatory Function.","date":"2017","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29186029","citation_count":59,"is_preprint":false},{"pmid":"8912645","id":"PMC_8912645","title":"Detection of a secreted MUC1/SEC protein by MUC1 isoform specific monoclonal antibodies.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8912645","citation_count":57,"is_preprint":false},{"pmid":"36479256","id":"PMC_36479256","title":"Expression of MUC1 in different tumours and its clinical significance (Review).","date":"2022","source":"Molecular and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36479256","citation_count":56,"is_preprint":false},{"pmid":"32427590","id":"PMC_32427590","title":"MUC1-C drives stemness in progression of colitis to colorectal cancer.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32427590","citation_count":56,"is_preprint":false},{"pmid":"16507569","id":"PMC_16507569","title":"Recycling of MUC1 is dependent on its palmitoylation.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16507569","citation_count":55,"is_preprint":false},{"pmid":"1713449","id":"PMC_1713449","title":"Production of MUC1 and MUC2 mucins by human tumor cell lines.","date":"1991","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/1713449","citation_count":54,"is_preprint":false},{"pmid":"27893710","id":"PMC_27893710","title":"MUC1-C activates BMI1 in human cancer cells.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27893710","citation_count":52,"is_preprint":false},{"pmid":"10578046","id":"PMC_10578046","title":"Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.","date":"1999","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10578046","citation_count":52,"is_preprint":false},{"pmid":"16094706","id":"PMC_16094706","title":"Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue.","date":"2005","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16094706","citation_count":51,"is_preprint":false},{"pmid":"9215126","id":"PMC_9215126","title":"MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas.","date":"1997","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9215126","citation_count":51,"is_preprint":false},{"pmid":"23608828","id":"PMC_23608828","title":"MUC1 as a potential target in anticancer therapies.","date":"2015","source":"American journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23608828","citation_count":50,"is_preprint":false},{"pmid":"15513966","id":"PMC_15513966","title":"MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.","date":"2004","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/15513966","citation_count":49,"is_preprint":false},{"pmid":"24292674","id":"PMC_24292674","title":"PPARγ E3 ubiquitin ligase regulates MUC1-C oncoprotein stability.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24292674","citation_count":48,"is_preprint":false},{"pmid":"11464247","id":"PMC_11464247","title":"MUC1 gene polymorphism in the gastric carcinogenesis pathway.","date":"2001","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11464247","citation_count":47,"is_preprint":false},{"pmid":"11922395","id":"PMC_11922395","title":"Androgen-dependent regulation of human MUC1 mucin expression.","date":"2002","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11922395","citation_count":46,"is_preprint":false},{"pmid":"38361923","id":"PMC_38361923","title":"MUC1 and MUC16: critical for immune modulation in cancer therapeutics.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38361923","citation_count":45,"is_preprint":false},{"pmid":"17600314","id":"PMC_17600314","title":"The signaling pathway involved in neutrophil elastase stimulated MUC1 transcription.","date":"2007","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17600314","citation_count":43,"is_preprint":false},{"pmid":"9537288","id":"PMC_9537288","title":"Androgen regulation of the Pem homeodomain gene in mice and rat Sertoli and epididymal cells.","date":"1998","source":"Journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/9537288","citation_count":43,"is_preprint":false},{"pmid":"33836774","id":"PMC_33836774","title":"Crosstalk between MUC1 and VEGF in angiogenesis and metastasis: a review highlighting roles of the MUC1 with an emphasis on metastatic and angiogenic signaling.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33836774","citation_count":42,"is_preprint":false},{"pmid":"34278474","id":"PMC_34278474","title":"MUC1 is an oncoprotein with a significant role in apoptosis (Review).","date":"2021","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34278474","citation_count":41,"is_preprint":false},{"pmid":"35462794","id":"PMC_35462794","title":"PEM-seq comprehensively quantifies DNA repair outcomes during gene-editing and DSB repair.","date":"2022","source":"STAR protocols","url":"https://pubmed.ncbi.nlm.nih.gov/35462794","citation_count":38,"is_preprint":false},{"pmid":"25925251","id":"PMC_25925251","title":"Muc1 is protective during kidney ischemia-reperfusion injury.","date":"2015","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25925251","citation_count":38,"is_preprint":false},{"pmid":"25759211","id":"PMC_25759211","title":"MUC1-mediated motility in breast cancer: a review highlighting the role of the MUC1/ICAM-1/Src signaling triad.","date":"2015","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/25759211","citation_count":38,"is_preprint":false},{"pmid":"18454162","id":"PMC_18454162","title":"Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.","date":"2008","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18454162","citation_count":38,"is_preprint":false},{"pmid":"27658423","id":"PMC_27658423","title":"MUC1-C Represses the Crumbs Complex Polarity Factor CRB3 and Downregulates the Hippo Pathway.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/27658423","citation_count":38,"is_preprint":false},{"pmid":"15253706","id":"PMC_15253706","title":"Homozygosity for uromodulin disorders: FJHN and MCKD-type 2.","date":"2004","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/15253706","citation_count":37,"is_preprint":false},{"pmid":"1283926","id":"PMC_1283926","title":"Expression of MUC1 and MUC2 mucins by human tumor cell lines.","date":"1992","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1283926","citation_count":37,"is_preprint":false},{"pmid":"28464016","id":"PMC_28464016","title":"MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28464016","citation_count":37,"is_preprint":false},{"pmid":"19711367","id":"PMC_19711367","title":"MUC1 is a substrate for gamma-secretase.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19711367","citation_count":36,"is_preprint":false},{"pmid":"32103170","id":"PMC_32103170","title":"MUC1 oncoprotein mitigates ER stress via CDA-mediated reprogramming of pyrimidine metabolism.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32103170","citation_count":36,"is_preprint":false},{"pmid":"21728842","id":"PMC_21728842","title":"MUC1 and MUC4: switching the emphasis from large to small.","date":"2011","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/21728842","citation_count":35,"is_preprint":false},{"pmid":"36184332","id":"PMC_36184332","title":"MUC1: An emerging target in cancer treatment and diagnosis.","date":"2022","source":"Bulletin du cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36184332","citation_count":34,"is_preprint":false},{"pmid":"31753595","id":"PMC_31753595","title":"Microbe-MUC1 Crosstalk in Cancer-Associated Infections.","date":"2019","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31753595","citation_count":33,"is_preprint":false},{"pmid":"18407586","id":"PMC_18407586","title":"MUC1 and colorectal cancer pathophysiology considerations.","date":"2008","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18407586","citation_count":33,"is_preprint":false},{"pmid":"31801904","id":"PMC_31801904","title":"MUC1 intracellular bioactivation mediates lung fibrosis.","date":"2019","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/31801904","citation_count":32,"is_preprint":false},{"pmid":"18767945","id":"PMC_18767945","title":"Strategies used for MUC1 immunotherapy: preclinical studies.","date":"2008","source":"Expert review of vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/18767945","citation_count":32,"is_preprint":false},{"pmid":"11421355","id":"PMC_11421355","title":"MUC1 in carcinoma-host interactions.","date":"2000","source":"Glycoconjugate journal","url":"https://pubmed.ncbi.nlm.nih.gov/11421355","citation_count":32,"is_preprint":false},{"pmid":"27092881","id":"PMC_27092881","title":"MUC1 stimulates EGFR expression and function in endometrial cancer.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27092881","citation_count":31,"is_preprint":false},{"pmid":"17524503","id":"PMC_17524503","title":"MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17524503","citation_count":31,"is_preprint":false},{"pmid":"19684334","id":"PMC_19684334","title":"Expression of human MUC1 during early pregnancy in the human MUC1 transgenic mouse model.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19684334","citation_count":31,"is_preprint":false},{"pmid":"19735652","id":"PMC_19735652","title":"Cortical anchorages and cell type segregations of maternal postplasmic/PEM RNAs in ascidians.","date":"2009","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/19735652","citation_count":30,"is_preprint":false},{"pmid":"8370537","id":"PMC_8370537","title":"Characterization and overexpression of the pem gene encoding pectin methylesterase of Erwinia chrysanthemi strain 3937.","date":"1993","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8370537","citation_count":30,"is_preprint":false},{"pmid":"10930667","id":"PMC_10930667","title":"Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice.","date":"2000","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/10930667","citation_count":30,"is_preprint":false},{"pmid":"36230728","id":"PMC_36230728","title":"Emergence of MUC1 in Mammals for Adaptation of Barrier Epithelia.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36230728","citation_count":29,"is_preprint":false},{"pmid":"30257347","id":"PMC_30257347","title":"Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30257347","citation_count":29,"is_preprint":false},{"pmid":"32219571","id":"PMC_32219571","title":"Identification of novel biomarkers, MUC5AC, MUC1, KRT7, GAPDH, CD44 for gastric cancer.","date":"2020","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32219571","citation_count":29,"is_preprint":false},{"pmid":"27347699","id":"PMC_27347699","title":"MUC1 in hematological malignancies.","date":"2016","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/27347699","citation_count":28,"is_preprint":false},{"pmid":"1383143","id":"PMC_1383143","title":"Protein energy malnutrition (PEM), brain and various facets of child development.","date":"1992","source":"Indian journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/1383143","citation_count":28,"is_preprint":false},{"pmid":"36516884","id":"PMC_36516884","title":"MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36516884","citation_count":28,"is_preprint":false},{"pmid":"10541345","id":"PMC_10541345","title":"Epithelial mucin-1 (MUC1) expression and MA5 anti-MUC1 monoclonal antibody targeting in multiple myeloma.","date":"1999","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/10541345","citation_count":28,"is_preprint":false},{"pmid":"24810688","id":"PMC_24810688","title":"Mucin 1 gene (MUC1) and gastric-cancer susceptibility.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24810688","citation_count":27,"is_preprint":false},{"pmid":"15696607","id":"PMC_15696607","title":"Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1).","date":"2004","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/15696607","citation_count":27,"is_preprint":false},{"pmid":"34976785","id":"PMC_34976785","title":"YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34976785","citation_count":27,"is_preprint":false},{"pmid":"26393683","id":"PMC_26393683","title":"Membrane-Tethered MUC1 Mucin Counter-Regulates the Phagocytic Activity of Macrophages.","date":"2016","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26393683","citation_count":27,"is_preprint":false},{"pmid":"12372344","id":"PMC_12372344","title":"Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells.","date":"2002","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12372344","citation_count":26,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47516,"output_tokens":8363,"usd":0.133996,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18049,"output_tokens":8112,"usd":0.146522,"stage2_stop_reason":"end_turn"},"total_usd":0.280518,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2007,\n      \"finding\": \"MUC1-C (C-terminal subunit) is N-glycosylated at Asn-36, and this N-glycosylation is required for upregulation of galectin-3 expression. N-glycosylated MUC1-C increases galectin-3 mRNA levels by suppressing miR-322, thereby stabilizing galectin-3 transcripts. In turn, galectin-3 binds to MUC1-C at the glycosylated Asn-36 site and forms a bridge between MUC1 and EGFR, making galectin-3 essential for EGF-mediated MUC1–EGFR interaction.\",\n      \"method\": \"In vitro glycosylation assays, miRNA suppression experiments, co-immunoprecipitation, mutagenesis of Asn-36\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, mutagenesis of glycosylation site, miRNA mechanistic follow-up, multiple orthogonal methods in single study\",\n      \"pmids\": [\"17889671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The MUC1 C-terminal subunit (MUC1-C) directly binds the ERα DNA-binding domain, stabilizes ERα by blocking its ubiquitination and proteasomal degradation, enhances ERα occupancy on estrogen-responsive promoters, and increases recruitment of p160 coactivators SRC-1 and GRIP1, thereby stimulating ERα-mediated transcription. The interaction is stimulated by 17β-estradiol.\",\n      \"method\": \"Co-immunoprecipitation, chromatin immunoprecipitation (ChIP), ubiquitination assay, transcription reporter assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct binding demonstrated, ChIP showing promoter occupancy, ubiquitination assay, multiple orthogonal methods in single study\",\n      \"pmids\": [\"16427018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MUC1-C associates with the gp130–JAK1–STAT3 complex; the MUC1-C cytoplasmic domain directly interacts with JAK1 and STAT3, and MUC1-C is required for JAK1-mediated STAT3 activation. In turn, activated STAT3 and MUC1-C co-occupy the MUC1 promoter, forming an autoinductive loop that drives MUC1 transcription.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, ChIP, siRNA knockdown, inhibitor (GO-201) treatment\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, ChIP, loss-of-function, multiple orthogonal methods in single study\",\n      \"pmids\": [\"21325207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MUC1-C binds directly to TAK1 and mediates association of TAK1 with TRAF6, activating NF-κB-mediated TAK1 transcription; in a positive feedback loop, TAK1-induced NF-κB signaling is further promoted by MUC1-C, linking MUC1-C to inflammatory NF-κB signaling in colon cancer.\",\n      \"method\": \"Co-immunoprecipitation, gene knockdown, NF-κB reporter assay, in vivo MUC1+/−/IL-10−/− mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding by Co-IP, in vivo model, reporter assay, multiple orthogonal methods\",\n      \"pmids\": [\"25659581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The Met receptor tyrosine kinase directly phosphorylates tyrosine at the YHPM motif in the MUC1 cytoplasmic tail (MUC1CT). HGF stimulation facilitates nuclear localization of MUC1CT. Met-phosphorylated MUC1CT enhances interaction with p53 and suppresses AP-1 activity at the MMP1 promoter, reducing MMP1 transcription and HGF-induced invasiveness.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, real-time confocal imaging for nuclear localization, ChIP/promoter reporter assay, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro kinase assay, live imaging, ChIP, multiple orthogonal methods in one study\",\n      \"pmids\": [\"18625714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MUC1 is dually palmitoylated at a CQC motif at the boundary of the transmembrane and cytoplasmic domains. Palmitoylation is not required for MUC1 delivery to the cell surface or endocytosis but is required for recycling from Rab11-positive endosomes back to the plasma membrane.\",\n      \"method\": \"[3H]palmitate metabolic labeling, mutagenesis of CQC motif, membrane trafficking rate constant calculations, EGFP-Rab11 co-localization, co-immunoprecipitation with AP-1\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical labeling, mutagenesis, quantitative trafficking assays, subcellular localization with functional consequence\",\n      \"pmids\": [\"16507569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MUC1 is a substrate for gamma-secretase: after TACE/ADAM17 ectodomain shedding, the resulting 15 kDa membrane-bound C-terminal fragment (CTF15) undergoes presenilin-dependent gamma-secretase cleavage. Mature nicastrin (the substrate receptor of gamma-secretase) co-immunoprecipitates with CTF15. Gamma-secretase inhibition causes CTF15 accumulation; subsequent degradation is non-proteasomal.\",\n      \"method\": \"Gamma-secretase inhibitors, TACE/ADAM17 inhibitors, nicastrin siRNA knockdown, co-immunoprecipitation of nicastrin with CTF15, Western blotting for cleavage products\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitors, siRNA, co-IP, multiple orthogonal methods establishing sequential proteolytic processing\",\n      \"pmids\": [\"19711367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PPARγ acts as an E3 ubiquitin ligase that binds MUC1-C and induces its proteasome-dependent ubiquitination and degradation, identifying Lys134 of MUC1-C as critical for PPARγ-mediated degradation; this terminates MUC1-C-mediated cell proliferation independently of PPARγ transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, site-directed mutagenesis (Lys134), proteasome inhibitor treatment, cell proliferation assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ubiquitination assay, mutagenesis, Co-IP, multiple orthogonal methods identifying the modification site\",\n      \"pmids\": [\"24292674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUC1-C drives MYC expression in multiple myeloma by occupying the MYC promoter via a β-catenin/TCF4-mediated mechanism; MUC1-C increases β-catenin occupancy on the MYC promoter and forms a complex with β-catenin and TCF4.\",\n      \"method\": \"CRISPR/Cas9 MUC1-C silencing, ChIP, co-immunoprecipitation, qRT-PCR, GO-203 inhibitor treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO, ChIP, Co-IP; multiple orthogonal methods; single lab\",\n      \"pmids\": [\"26907633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUC1-C drives BMI1 transcription by a MYC-dependent mechanism and blocks miR-200c-mediated BMI1 downregulation. MUC1-C directly binds BMI1 and promotes BMI1 occupancy on the CDKN2A (p16INK4a) promoter, linking MUC1-C to PRC1-mediated epigenetic silencing of p16INK4a.\",\n      \"method\": \"Co-immunoprecipitation, ChIP, miRNA reporter assay, gene silencing, inhibitor (GO-203) treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding Co-IP, ChIP, miRNA mechanistic assays, multiple orthogonal methods\",\n      \"pmids\": [\"27893710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUC1-C associates with ZEB1 on the CRB3 promoter to repress CRB3 transcription. Loss of CRB3 suppresses the Hippo pathway (reduced LATS1/2 phosphorylation), activating YAP. MUC1-C then interacts with YAP, promotes YAP/β-catenin complex formation, and induces WNT target MYC expression.\",\n      \"method\": \"ChIP, co-immunoprecipitation, siRNA knockdown, promoter reporter assay, phosphorylation analysis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, Co-IP, multiple loss-of-function experiments, multiple orthogonal methods\",\n      \"pmids\": [\"27658423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MUC1 cytoplasmic tail sequesters β-catenin away from E-cadherin, reduces β-catenin nuclear translocation, decreases LEF-1 activation, and suppresses cyclin D1 and c-Myc expression, resulting in inhibition of cell proliferation.\",\n      \"method\": \"Transfection of MUC1 cytoplasmic tail (CD8/MUC1 fusion), co-immunoprecipitation, luciferase reporter (LEF-1), Western blotting for cyclin D1/c-Myc, proliferation assay with Muc1+/+ vs. Muc1−/− primary cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, reporter assay, KO comparison, multiple orthogonal methods\",\n      \"pmids\": [\"17524503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"MUC1 (CD227) cytoplasmic domain is tyrosine-phosphorylated upon T cell receptor (TCR) ligation and associates with the Src-family kinase p56lck in Jurkat T cells and normal human T cells. MUC1 knockdown by siRNA reduces TCR-mediated Ca2+ influx, ERK1/2 phosphorylation, CD69 expression, proliferation, and IL-2 production.\",\n      \"method\": \"Co-immunoprecipitation of MUC1 with p56lck, low-density membrane fractionation, siRNA knockdown, flow cytometry, Ca2+ flux measurement\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, membrane fractionation, siRNA with defined signaling readouts, multiple orthogonal methods\",\n      \"pmids\": [\"15513966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Muc1 mucins expressed on the cell surface serve as adhesion sites for Pseudomonas aeruginosa; deletion of the extracellular domain by mutation or proteolytic cleavage with neutrophil elastase abolishes bacterial adhesion to Muc1-expressing CHO cells.\",\n      \"method\": \"Stable transfection of hamster Muc1 cDNA into CHO cells, bacterial adhesion assay, neutrophil elastase cleavage, extracellular domain deletion mutant\",\n      \"journal\": \"American journal of physiology. Lung cellular and molecular physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional adhesion assay with deletion mutagenesis and enzymatic cleavage, clear mechanistic dissection\",\n      \"pmids\": [\"11133508\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Neutrophil elastase stimulates MUC1 transcription in lung epithelial cells via a PKCδ→Duox1→ROS→TACE→TNF-α→TNFR1→ERK1/2→Sp1 signaling pathway, distinct from the MUC5AC pathway which shares components only up to TACE.\",\n      \"method\": \"Pharmacological inhibitors, dominant-negative mutants, RNA interference, soluble receptor blocking, transcription reporter assay\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple inhibitors, dominant-negative mutants, RNAi, and reporter assays defining a complete pathway in one study\",\n      \"pmids\": [\"17600314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TGF-β1 phosphorylates SMAD3, which increases phosphorylation of MUC1-CT at Thr41 and Tyr46, activating β-catenin to form phospho-SMAD3/MUC1-CT and MUC1-CT/β-catenin nuclear complexes that promote myofibroblast transition, cell senescence, and fibroblast proliferation. Galectin-3 directly activates MUC1-CT and serves as a bridge between the TGF-β receptor and MUC1-C, providing TGF-β1-independent activation. Inhibition of MUC1-CT nuclear translocation (GO-201 or siRNA) or Muc1 knockout reduces bleomycin-induced lung fibrosis.\",\n      \"method\": \"Phosphorylation analysis (Thr41/Tyr46), co-immunoprecipitation, nuclear fractionation, siRNA, GO-201 inhibitor, MUC1-knockout mice + bleomycin model, in vitro myofibroblast transition assays\",\n      \"journal\": \"Thorax\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro mechanistic dissection with phospho-specific analysis, Co-IP, in vivo KO model, multiple orthogonal methods across two laboratories' contexts\",\n      \"pmids\": [\"31801904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In ischemia-reperfusion injury, Muc1 translocates from the apical surface to the cytoplasm and nucleus of renal tubular epithelia. Muc1 knockout mice show worse kidney damage, reduced HIF-1α levels, reduced induction of HIF-1 target glycolytic genes, and prolonged AMPK activation, indicating that Muc1 enhances the HIF-1α protective pathway during ischemic stress.\",\n      \"method\": \"Immunofluorescence localization (apical→cytoplasmic/nuclear shift), Muc1 knockout mice + IRI model, HIF-1α protein measurement, qPCR for HIF-1 target genes, AMPK activation assay\",\n      \"journal\": \"American journal of physiology. Renal physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization with functional consequence, KO mouse phenotype, multiple molecular readouts\",\n      \"pmids\": [\"25925251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MUC1-C upregulates CDA (cytidine deaminase) expression by occupying the CDA promoter upon ER stress induction, increasing CDA activity and driving deoxycytidine-to-deoxyuridine metabolic reprogramming. The resulting deoxyuridine mitigates ER stress-induced cytotoxicity and ROS, providing cancer cell survival advantage.\",\n      \"method\": \"ChIP showing MUC1-C occupancy on CDA promoter, CDA activity assay, transcriptomic analysis, metabolomic analysis, MUC1 knockdown, CDA/pathway inhibitors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — ChIP, enzymatic activity assay, metabolomics, loss-of-function; multiple orthogonal methods\",\n      \"pmids\": [\"32103170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUC1 stimulates EGFR gene expression in endometrial cancer: MUC1 directly binds to two regions of the EGFR promoter (−627/−511 and −172/−64), and MUC1 knockout (CRISPR/Cas9) or siRNA knockdown reduces EGFR mRNA, protein, and downstream signaling.\",\n      \"method\": \"siRNA knockdown, CRISPR/Cas9 knockout, ChIP showing MUC1 binding to EGFR promoter, Western blotting, qPCR, proliferation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, CRISPR KO, siRNA, multiple functional readouts; single lab, orthogonal methods\",\n      \"pmids\": [\"27092881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MUC1-C suppresses androgen receptor (AR) axis signaling and induces BRN2 via a MYC→BRN2 pathway; it also induces MYCN, EZH2, and neuroendocrine markers (ASCL1, AURKA, SYP), suppresses p53, and induces Yamanaka pluripotency factors (OCT4, SOX2, KLF4, MYC), driving cancer stem cell self-renewal and lineage plasticity toward neuroendocrine prostate cancer.\",\n      \"method\": \"siRNA knockdown, CRISPR editing, inhibitor treatment, ChIP for promoter occupancy, gene expression analysis, self-renewal (sphere formation) and tumorigenicity assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR, ChIP, multiple signaling readouts; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"31953400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MUC1-C binds directly to β-catenin and EGFR through tandem sequences in its cytoplasmic domain; a MUC1 inhibitory peptide (PMIP) blocks both MUC1/β-catenin and MUC1/EGFR interactions in a dominant-negative fashion, induces ligand-dependent EGFR degradation, and reduces breast cancer cell proliferation, migration, invasion, and tumor growth in vivo.\",\n      \"method\": \"Peptide competition assay, co-immunoprecipitation, receptor degradation assay, in vitro proliferation/migration/invasion assays, SCID mouse xenograft model, MMTV-pyVmT transgenic mouse model\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP with peptide competition, in vivo mouse models, multiple cell-based phenotypic assays\",\n      \"pmids\": [\"19118037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Muc1 null mice develop bacterial conjunctivitis (coagulase-negative Staphylococcus, Streptococcus type alpha, Corynebacterium group G2) at significantly higher rates than wild-type mice, establishing that Muc1 plays a critical protective role at the ocular epithelial surface against bacterial infection.\",\n      \"method\": \"Muc1 knockout mouse model, bacterial speciation of infected tissue, immunofluorescence for Muc1 protein in conjunctiva/Harderian gland, Northern blot/RT-PCR for transcript\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse model with defined infectious phenotype, molecular confirmation of Muc1 in affected tissue\",\n      \"pmids\": [\"10359313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MUC1/Muc1 is predominantly expressed in classically activated (M1) macrophages; MUC1/Muc1-deficiency increases macrophage adhesion and phagocytosis of P. aeruginosa and E. coli, and augments ROS production and TNF-α release, demonstrating that MUC1 counter-regulates macrophage phagocytic activity in an anti-inflammatory manner. M1 polarization and Pa stimulation increase MUC1 ectodomain shedding via TACE.\",\n      \"method\": \"Muc1 knockout macrophages (M0/M1/M2 polarization), phagocytosis assays, ROS measurement, ELISA for TNF-α, TACE inhibitor, flow cytometry\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO cells with defined functional readouts, multiple cell types, pharmacological confirmation of shedding mechanism\",\n      \"pmids\": [\"26393683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A secreted MUC1 isoform (MUC1/SEC), produced by alternative splicing incorporating intron 2 sequence and lacking a transmembrane domain, is expressed at the protein level by breast cancer cells and is detectable in sera of breast cancer patients.\",\n      \"method\": \"Generation of isoform-specific monoclonal antibodies against the unique sec peptide, Western blotting of secreted proteins, immunoreactivity with recombinant MUC1/SEC, inhibition by sec peptide\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific antibodies, recombinant protein validation, peptide competition; single lab\",\n      \"pmids\": [\"8912645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"MUC1 cytoplasmic domain is tyrosine-phosphorylated in activated human T cells and dendritic cells (DC), and associates with other phosphoproteins, indicating a role in signal transduction in these hematopoietic cells.\",\n      \"method\": \"Flow cytometry for CD227 expression, phosphotyrosine Western blotting of CD227 immunoprecipitates from activated T cells and DC, in vitro DC culture activation\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP/phosphoblot, confirmed in two cell types (T cells and DC), single lab\",\n      \"pmids\": [\"12377938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MUC1 induces acquired chemoresistance by upregulating ABCB1 (P-glycoprotein) through EGFR activation and nuclear translocation; targeted suppression of EGFR or ABCB1 reverses MUC1-mediated drug resistance in vitro and in xenograft models.\",\n      \"method\": \"Gain- and loss-of-function MUC1 models, shRNA and inhibitors targeting EGFR and ABCB1, xenograft mouse model, Western blotting for EGFR nuclear translocation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss/gain-of-function, in vivo model, pharmacological rescue; single lab, pathway inferred from inhibitor experiments\",\n      \"pmids\": [\"28796259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MUC1 expression enhances glycolysis, pentose phosphate pathway flux, and nucleotide biosynthesis in pancreatic cancer cells, conferring radiation resistance by maintaining high nucleotide pools and reducing DNA damage; glycolysis inhibition with 3-bromopyruvate abrogates MUC1-mediated radiation resistance both in vitro and in vivo.\",\n      \"method\": \"MUC1 knockdown and overexpression models, metabolomic analysis, clonogenicity and cytotoxicity assays, DNA damage (γH2AX) measurement, 3-bromopyruvate rescue in vitro and in vivo xenograft\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomics, functional rescue with glycolysis inhibitor, in vivo model; single lab\",\n      \"pmids\": [\"28720669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Muc1 expression in rabbit uterine epithelium is upregulated ~10-fold by progesterone and dramatically reduced locally at implantation sites; blastocyst-derived signals (demonstrated by coculture of uterine epithelial cells with trophoblastic vesicles) locally remove Muc1 from the apical epithelial surface, facilitating embryo attachment.\",\n      \"method\": \"Northern blot for Muc1 mRNA at defined pregnancy stages, immunofluorescence localization, short-term coculture of uterine epithelial cells with trophoblastic vesicles\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — Northern blot quantitation, immunofluorescence, and ex vivo coculture; single lab with multiple complementary approaches\",\n      \"pmids\": [\"9421424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"YBX1 transcription factor directly binds the MUC1 promoter at position −1480/−1476 and activates MUC1 transcription, contributing to lung adenocarcinoma stemness and metastasis downstream of YBX1.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, YBX1 silencing/overexpression with MUC1 rescue, xenograft and metastasis mouse models\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay define direct transcriptional regulation; single lab\",\n      \"pmids\": [\"34976785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MUC1-C enhances stability of EGFRvIII in glioblastoma by preventing its lysosomal degradation; MUC1-C knockdown increases EGFRvIII-lysosome colocalization. MUC1-C upregulation in EGFRvIII-positive cells occurs via NF-κB, forming a positive feedback loop between EGFRvIII and MUC1.\",\n      \"method\": \"CRISPR-Cas9 library screening, siRNA knockdown, immunofluorescence colocalization with lysosome markers, NF-κB pathway inhibitor, Western blotting\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen, siRNA, colocalization; single lab, mechanism partially inferred\",\n      \"pmids\": [\"36516884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MUC1 and c-Met interact physically in hepatocellular carcinoma (HCC) cells; HGF-induced c-Met phosphorylation decreases this interaction and downregulates MUC1 expression. Conversely, MUC1 siRNA silencing increases HGF-induced c-Met activation and cell motility/invasion via the β-catenin/c-Myc pathway.\",\n      \"method\": \"Co-immunoprecipitation of MUC1 and c-Met, siRNA silencing, c-Met inhibitor, migration/invasion assays, β-catenin/c-Myc Western blotting\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP, siRNA with functional readouts, pharmacological inhibition; single lab\",\n      \"pmids\": [\"22962849\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MUC1 is a heterodimeric transmembrane mucin whose N-terminal subunit (MUC1-N) forms a protective apical mucous barrier, while the C-terminal subunit (MUC1-C) acts as a signaling hub: it is proteolytically shed by TACE/ADAM17 and further cleaved by presenilin-dependent gamma-secretase; the cytoplasmic tail undergoes tyrosine phosphorylation by kinases including Met and Lck, serine/threonine phosphorylation by TGF-β/SMAD3, and S-palmitoylation at a CQC motif that controls endosomal recycling; phosphorylated MUC1-C directly interacts with ERα, JAK1, STAT3, β-catenin, TCF4, BMI1, TAK1/TRAF6, p56lck, galectin-3/EGFR, and p53 to modulate transcription (ERα target genes, MYC, STAT3, NF-κB/TAK1, CRB3, CDA, EGFR), epigenetic reprogramming (PRC1/BMI1-H2A ubiquitylation, p16INK4a silencing), metabolic reprogramming (glycolysis, nucleotide biosynthesis, pyrimidine metabolism via CDA), and cellular processes including cell polarity loss, inflammation, stem cell self-renewal, and lineage plasticity; in normal epithelia MUC1 serves as a bacterial adhesion/binding site and counter-regulates excessive TLR-mediated inflammation, protects renal tubules during ischemia via HIF-1α enhancement, and its surface expression is dynamically controlled by progesterone and blastocyst-derived signals in the uterus.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MUC1 is a transmembrane mucin processed into two subunits whose membrane-tethered C-terminal subunit (MUC1-C) functions as a signal-transducing oncoprotein, while the cell-surface ectodomain provides a protective epithelial barrier [#13, #20]. At the surface, MUC1 serves as an adhesion site for bacteria such as Pseudomonas aeruginosa and counter-regulates inflammatory responses, with knockout animals showing increased ocular and conjunctival infection and macrophage hyperactivation [#13, #21, #22]. MUC1-C is subject to sequential proteolytic processing: TACE/ADAM17 sheds the ectodomain to generate a membrane-bound C-terminal fragment that is then cleaved by presenilin-dependent gamma-secretase [#6, #22]. Its cytoplasmic tail is a phosphorylation hub, tyrosine-phosphorylated by the Met receptor and by the Src-family kinase p56lck following T-cell receptor ligation, and serine/threonine-phosphorylated downstream of TGF-\\u03b21/SMAD3, with N-glycosylation at Asn-36 and palmitoylation at a CQC motif governing galectin-3-bridged EGFR association and Rab11-dependent endosomal recycling, respectively [#0, #4, #5, #12, #15]. Once activated, MUC1-C directly binds an array of transcriptional and signaling partners\\u2014ER\\u03b1, JAK1/STAT3, TAK1/TRAF6, \\u03b2-catenin/TCF4, BMI1, YAP/ZEB1, and p53\\u2014to drive target-gene programs including ER\\u03b1-responsive genes, MYC, EGFR, CDA, and NF-\\u03baB-dependent transcription, frequently through autoinductive feedback loops [#1, #2, #3, #8, #9, #10, #18]. Through these circuits MUC1-C promotes epigenetic silencing of CDKN2A/p16INK4a via PRC1/BMI1, metabolic reprogramming toward glycolysis and nucleotide biosynthesis, and cancer stem-cell self-renewal and neuroendocrine lineage plasticity [#9, #17, #20, #26]. In normal physiology MUC1 enhances HIF-1\\u03b1-mediated protection of renal tubules during ischemia, while its expression is hormonally and developmentally controlled at the uterine surface during implantation [#16, #27]. MUC1-C abundance is itself terminated by PPAR\\u03b3-mediated ubiquitination at Lys134 [#7].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that MUC1 is not exclusively membrane-bound, defining a secreted splice isoform detectable in cancer patient sera and broadening the protein's potential extracellular roles.\",\n      \"evidence\": \"Isoform-specific monoclonal antibodies and Western blotting of breast cancer secretions and patient sera\",\n      \"pmids\": [\"8912645\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Functional role of the secreted isoform not defined\", \"Relationship to the transmembrane signaling functions unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Resolved how MUC1 surface levels are regulated in reproduction, showing hormonal induction and local embryo-driven removal to permit implantation.\",\n      \"evidence\": \"Northern blot, immunofluorescence, and uterine epithelial/trophoblastic vesicle coculture in rabbit\",\n      \"pmids\": [\"9421424\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular nature of the blastocyst-derived signal not identified\", \"Mechanism of local MUC1 removal undefined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined MUC1's protective barrier function in vivo, demonstrating that its loss predisposes epithelial surfaces to bacterial infection.\",\n      \"evidence\": \"Muc1 knockout mice with bacterial speciation of conjunctival infection\",\n      \"pmids\": [\"10359313\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Molecular basis of anti-bacterial protection not dissected here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified the molecular basis of MUC1's barrier role by showing the ectodomain acts as a bacterial adhesion site.\",\n      \"evidence\": \"Muc1 transfection of CHO cells, bacterial adhesion assays, elastase cleavage and deletion mutants\",\n      \"pmids\": [\"11133508\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Receptor/ligand pairing with bacterial adhesins not defined\", \"Whether adhesion is protective or facilitates colonization not resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed the MUC1 cytoplasmic tail participates in immune signal transduction, linking it to TCR-proximal kinase activity.\",\n      \"evidence\": \"Co-IP with p56lck, membrane fractionation, siRNA with Ca2+ flux/ERK/CD69/IL-2 readouts in T cells\",\n      \"pmids\": [\"15513966\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Direct kinase-substrate phosphorylation site on MUC1 not mapped\", \"Whether p56lck phosphorylates MUC1 directly not shown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established MUC1-C as a direct transcriptional cofactor by showing it stabilizes ER\\u03b1 and enhances estrogen-responsive transcription.\",\n      \"evidence\": \"Co-IP, ChIP, ubiquitination and reporter assays with 17\\u03b2-estradiol stimulation\",\n      \"pmids\": [\"16427018\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Whether nuclear MUC1-C requires prior cleavage not addressed\", \"Generality across non-breast contexts unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined a post-translational control of MUC1 trafficking, showing palmitoylation at the CQC motif governs endosomal recycling.\",\n      \"evidence\": \"[3H]palmitate labeling, CQC mutagenesis, trafficking rate constants, Rab11 colocalization, AP-1 Co-IP\",\n      \"pmids\": [\"16507569\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Palmitoyltransferase responsible not identified\", \"Link between recycling and signaling output not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Connected MUC1-C glycosylation to receptor signaling, showing Asn-36 N-glycosylation enables galectin-3-bridged MUC1\\u2013EGFR association.\",\n      \"evidence\": \"Glycosylation assays, Asn-36 mutagenesis, miR-322 suppression, reciprocal Co-IP\",\n      \"pmids\": [\"17889671\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural basis of the galectin-3 bridge not resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed a tumor-suppressive facet of the cytoplasmic tail by showing it sequesters \\u03b2-catenin to restrain proliferative transcription.\",\n      \"evidence\": \"CD8/MUC1 fusion transfection, Co-IP, LEF-1 reporter, Muc1+/+ vs -/- proliferation\",\n      \"pmids\": [\"17524503\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Reconciliation with later \\u03b2-catenin/TCF4-driven MYC activation context-dependent and unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapped a complete signaling cascade by which neutrophil elastase induces MUC1 transcription, distinguishing it from MUC5AC regulation.\",\n      \"evidence\": \"Inhibitors, dominant-negatives, RNAi, and reporter assays in lung epithelial cells\",\n      \"pmids\": [\"17600314\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"In vivo relevance of the PKC\\u03b4\\u2192Duox1\\u2192TACE\\u2192Sp1 axis not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Met as a direct MUC1 cytoplasmic-tail kinase and linked HGF signaling to nuclear MUC1 and p53-dependent transcriptional output.\",\n      \"evidence\": \"In vitro kinase assay, live-cell nuclear imaging, ChIP/reporter at MMP1 promoter\",\n      \"pmids\": [\"18625714\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"How phosphorylation drives nuclear import mechanistically not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Completed the proteolytic processing model by demonstrating gamma-secretase cleaves the membrane-bound MUC1 C-terminal fragment after ectodomain shedding.\",\n      \"evidence\": \"Gamma-secretase and TACE inhibitors, nicastrin siRNA and Co-IP, cleavage-product Westerns\",\n      \"pmids\": [\"19711367\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Fate and signaling role of the released intracellular fragment not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Pinpointed tandem cytoplasmic sequences mediating direct \\u03b2-catenin and EGFR binding and validated them as druggable with a dominant-negative peptide.\",\n      \"evidence\": \"Peptide competition, Co-IP, EGFR degradation assay, xenograft and MMTV-pyVmT models\",\n      \"pmids\": [\"19118037\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Structural detail of the binding interfaces not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed MUC1-C is required for JAK1-driven STAT3 activation and forms an autoinductive transcriptional loop at its own promoter.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP, siRNA, GO-201 inhibitor\",\n      \"pmids\": [\"21325207\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Whether MUC1-C directly enhances JAK1 catalytic activity not shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated context-dependence of the MUC1\\u2013c-Met axis, with MUC1 restraining HGF-induced c-Met activation and invasion in HCC.\",\n      \"evidence\": \"Co-IP, siRNA, c-Met inhibitor, migration/invasion assays in HCC cells\",\n      \"pmids\": [\"22962849\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Single Co-IP without reciprocal validation in this system\", \"Reconciliation with Met-driven pro-tumor MUC1 signaling elsewhere unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified a mechanism terminating MUC1-C signaling, revealing PPAR\\u03b3 as an E3 ligase that ubiquitinates MUC1-C at Lys134 for degradation.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, Lys134 mutagenesis, proteasome inhibitor, proliferation assay\",\n      \"pmids\": [\"24292674\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Physiological signals controlling PPAR\\u03b3 ligase activity toward MUC1-C unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked MUC1-C to inflammatory NF-\\u03baB signaling via direct TAK1/TRAF6 binding in a positive feedback loop relevant to colon cancer.\",\n      \"evidence\": \"Co-IP, knockdown, NF-\\u03baB reporter, MUC1+/-/IL-10-/- mouse model\",\n      \"pmids\": [\"25659581\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Whether MUC1-C enhances TAK1 kinase activity directly not shown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined a cytoprotective role in renal ischemia, showing MUC1 traffics to the nucleus and enhances HIF-1\\u03b1 stabilization and glycolytic gene induction.\",\n      \"evidence\": \"Immunofluorescence localization, Muc1 KO + IRI model, HIF-1\\u03b1 and AMPK measurements\",\n      \"pmids\": [\"25925251\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Direct MUC1\\u2013HIF-1\\u03b1 interaction not demonstrated\", \"Mechanism of HIF-1\\u03b1 stabilization unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a MUC1-C/\\u03b2-catenin/TCF4 transcriptional mechanism driving MYC in multiple myeloma.\",\n      \"evidence\": \"CRISPR silencing, ChIP, Co-IP, qRT-PCR, GO-203 inhibitor\",\n      \"pmids\": [\"26907633\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Determinants of \\u03b2-catenin promoter recruitment by MUC1-C not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked MUC1-C to PRC1-mediated epigenetic silencing of p16INK4a through MYC-dependent BMI1 induction and direct BMI1 binding.\",\n      \"evidence\": \"Co-IP, ChIP, miR-200c reporter, gene silencing, GO-203\",\n      \"pmids\": [\"27893710\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Direct effect on H2A ubiquitylation not measured here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected MUC1-C to Hippo/YAP and WNT crosstalk by repressing CRB3 with ZEB1 and forming YAP/\\u03b2-catenin complexes.\",\n      \"evidence\": \"ChIP, Co-IP, siRNA, promoter reporter, LATS1/2 phosphorylation analysis\",\n      \"pmids\": [\"27658423\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Order of events between CRB3 repression and polarity loss not fully resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed MUC1 acts as a direct transcriptional activator of EGFR by binding its promoter in endometrial cancer.\",\n      \"evidence\": \"siRNA, CRISPR KO, ChIP at two EGFR promoter regions, qPCR/Western, proliferation\",\n      \"pmids\": [\"27092881\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Cofactors required for MUC1 promoter occupancy not identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined MUC1 as an anti-inflammatory counter-regulator of macrophage phagocytosis and cytokine output, predominantly in M1 macrophages.\",\n      \"evidence\": \"Muc1 KO macrophages, phagocytosis/ROS/TNF-\\u03b1 assays, TACE inhibitor\",\n      \"pmids\": [\"26393683\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Downstream signaling restraining phagocytosis not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked MUC1 to acquired chemoresistance via EGFR-driven ABCB1 upregulation.\",\n      \"evidence\": \"Gain/loss-of-function, EGFR/ABCB1 shRNA and inhibitors, xenografts\",\n      \"pmids\": [\"28796259\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Pathway inferred from inhibitor experiments rather than direct binding\", \"Direct MUC1 occupancy at ABCB1 not shown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established MUC1-driven metabolic reprogramming as a basis for radiation resistance through elevated glycolysis and nucleotide pools.\",\n      \"evidence\": \"Knockdown/overexpression, metabolomics, \\u03b3H2AX, 3-bromopyruvate rescue in vitro and in vivo\",\n      \"pmids\": [\"28720669\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Transcriptional/enzymatic targets mediating glycolytic shift not all defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a TGF-\\u03b21/SMAD3 phosphorylation mechanism on MUC1-CT (Thr41/Tyr46) driving fibrosis, with galectin-3 providing a TGF-\\u03b2-independent bridge.\",\n      \"evidence\": \"Phospho-specific analysis, Co-IP, nuclear fractionation, siRNA/GO-201, Muc1 KO + bleomycin model\",\n      \"pmids\": [\"31801904\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Kinase directly phosphorylating Tyr46 downstream of SMAD3 not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected MUC1-C to pyrimidine metabolic reprogramming under ER stress by transcriptionally activating CDA for survival.\",\n      \"evidence\": \"ChIP at CDA promoter, CDA activity assay, transcriptomics/metabolomics, knockdown, inhibitors\",\n      \"pmids\": [\"32103170\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Cofactors recruiting MUC1-C to the CDA promoter not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established MUC1-C as a driver of lineage plasticity and stemness, suppressing AR and p53 while inducing pluripotency and neuroendocrine programs.\",\n      \"evidence\": \"siRNA, CRISPR, ChIP, sphere formation and tumorigenicity assays in prostate cancer\",\n      \"pmids\": [\"31953400\"],\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Hierarchy among the many induced factors not fully ordered\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified YBX1 as a direct upstream transcriptional activator of MUC1 contributing to lung adenocarcinoma stemness and metastasis.\",\n      \"evidence\": \"ChIP, dual-luciferase reporter, YBX1 silencing/overexpression with MUC1 rescue, mouse models\",\n      \"pmids\": [\"34976785\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Single-lab finding; broader generality of YBX1 control of MUC1 untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed a post-translational MUC1-C function stabilizing EGFRvIII against lysosomal degradation within an NF-\\u03baB feedback loop in glioblastoma.\",\n      \"evidence\": \"CRISPR screen, siRNA, lysosome colocalization, NF-\\u03baB inhibitor, Western blotting\",\n      \"pmids\": [\"36516884\"],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"Mechanism by which MUC1-C diverts EGFRvIII from lysosomes not defined\", \"Mechanism partially inferred\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MUC1-C reconciles its context-dependent tumor-suppressive (\\u03b2-catenin sequestration, c-Met restraint) versus oncogenic (\\u03b2-catenin/TCF4-MYC, EGFR amplification) roles, and the structural basis of its many direct interactions, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"\",\n      \"gaps\": [\"No structural model of MUC1-C interaction interfaces\", \"Determinants switching MUC1-C between suppressive and oncogenic outputs unknown\", \"Rules governing nuclear translocation versus membrane signaling undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 8, 9, 17, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 3, 4, 12]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [13]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 3, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 13, 16]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 15, 16]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 4, 12, 20]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 2, 8, 9, 17, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [12, 21, 22]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 26]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGFR\", \"CTNNB1\", \"STAT3\", \"JAK1\", \"ESR1\", \"TCF4\", \"BMI1\", \"TAK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}